Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell Transplantation for Non-malignant Blood and Immune System Diseases
Latest Information Update: 01 Apr 2025
At a glance
- Drugs Anti-CD7 chimeric antigen receptor T cell therapy-Yake Biotechnology (Primary)
- Indications Aplastic anaemia; Bone marrow disorders; Dyskeratosis congenita; Fanconi's anaemia; Neutropenia; Thrombocytopenia
- Focus Adverse reactions; Therapeutic Use
- 01 Apr 2025 New trial record